-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
G Medical Innovations (NASDAQ:GMVD) and Stryker (NYSE:SYK) Head-To-Head Survey
G Medical Innovations (NASDAQ:GMVD) and Stryker (NYSE:SYK) Head-To-Head Survey
Stryker (NYSE:SYK – Get Rating) and G Medical Innovations (NASDAQ:GMVD – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Stryker and G Medical Innovations, as provided by MarketBeat.
Get Stryker alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Stryker | 0 | 8 | 12 | 0 | 2.60 |
G Medical Innovations | 0 | 0 | 0 | 0 | N/A |
Stryker currently has a consensus target price of $270.53, indicating a potential upside of 35.66%. Given Stryker's higher possible upside, equities research analysts plainly believe Stryker is more favorable than G Medical Innovations.
Valuation and Earnings
This table compares Stryker and G Medical Innovations' gross revenue, earnings per share (EPS) and valuation.Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Stryker | $17.11 billion | 4.41 | $1.99 billion | $5.26 | 37.91 |
G Medical Innovations | N/A | N/A | N/A | N/A | N/A |
Stryker has higher revenue and earnings than G Medical Innovations.
Insider and Institutional Ownership
74.5% of Stryker shares are owned by institutional investors. 6.7% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Stryker and G Medical Innovations' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Stryker | 11.56% | 24.09% | 10.07% |
G Medical Innovations | N/A | N/A | N/A |
Summary
Stryker beats G Medical Innovations on 8 of the 8 factors compared between the two stocks.
About Stryker
(Get Rating)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
About G Medical Innovations
(Get Rating)
G Medical Innovations Holdings Ltd, together with its subsidiaries, an early commercial stage healthcare company, engages in the development of next generation mobile health and telemedicine solutions in the United States, China, and Israel. The company's products include Prizma, a plug-and-play medical device that measures vital signs with electronic medical records functionality and clinical grade reporting standards; and Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiogram data continuously for up to 14 days. It also develops Wireless Vital Signs Monitoring System, a solution that provides continuous real time monitoring of vital signs and biometrics. In addition, it offers monitoring services, including independent diagnostic testing facility monitoring and private monitoring services. The company was incorporated in 2014 and is based in Rehovot, Israel.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
史赛克(NYSE:SYK-GET Rating)和G医疗创新(纳斯达克:GMVD-GET Rating)都是医药公司,但哪只股票更好?我们将根据两家公司的风险、股息、估值、机构所有权、盈利能力、收益和分析师建议的强弱对它们进行比较。
分析师评级
这是MarketBeat提供的Stryker和G医疗创新公司最近的评级和推荐细目。
到达史崔克警报:销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
史崔克 | 0 | 8个 | 12 | 0 | 2.60 |
G医疗创新 | 0 | 0 | 0 | 0 | 不适用 |
Stryker目前的共识目标价为270.53美元,表明潜在上行空间为35.66%。考虑到Stryker更有可能的上行空间,股票研究分析师显然认为Stryker比G Medical Innovation更有利。
估值和收益
此表比较了Stryker和G医疗创新公司的毛收入、每股收益(EPS)和估值。总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
史崔克 | 171.1亿美元 | 4.41 | 19.9亿美元 | 5.26美元 | 37.91 |
G医疗创新 | 不适用 | 不适用 | 不适用 | 不适用 | 不适用 |
Stryker的收入和收益比G医疗创新公司高。
内部人与机构持股
Stryker 74.5%的股份由机构投资者持有。Stryker 6.7%的股份由内部人士持有。强大的机构持股表明,对冲基金、捐赠基金和大型基金管理公司相信,一只股票的长期表现将好于大盘。
盈利能力
此表比较了Stryker和G Medical Innovation的净利润率、股本回报率和资产回报率。
净利润率 | 股本回报率 | 资产回报率 | |
史崔克 | 11.56% | 24.09% | 10.07% |
G医疗创新 | 不适用 | 不适用 | 不适用 |
摘要
Stryker在两只股票比较的8个因素中有8个击败了G医疗创新公司。
关于史崔克
(获取评级)
Stryker公司是一家医疗技术公司。该公司通过两个部门运营,MedSurg和Neurotech,以及骨科和脊柱。整形外科和脊柱部门提供用于髋关节和膝关节置换以及创伤和四肢手术的植入物。这一细分市场还提供脊柱植入产品,包括用于脊柱损伤、畸形和退行性治疗的颈椎、胸腰椎和椎间系统。MedSurg和Neurotech部门提供外科设备和外科导航系统、内窥镜和通信系统、病人处理、紧急医疗设备和重症监护一次性产品、再加工和再制造医疗器械,以及用于各种医疗专科的其他医疗器械产品。这一细分市场还提供神经技术产品,包括用于微创血管内技术的产品;用于脑和开放颅骨外科手术的产品;矫形生物学和生物外科产品,如合成骨移植和椎体增强产品;用于治疗急性缺血性和出血性中风的微创产品;以及颅颌面植入产品,包括颅骨、颌面和胸壁设备,以及硬脑膜替代品和密封剂。该公司通过公司拥有的子公司和分支机构,以及大约75个国家和地区的第三方经销商和分销商,向医生、医院和其他医疗机构销售其产品。Stryker Corporation成立于1941年,总部设在密歇根州卡拉马祖。
关于G医疗创新
(获取评级)
G医疗创新控股有限公司及其子公司是一家处于早期商业阶段的医疗保健公司,致力于在美国、中国和以色列开发下一代移动医疗和远程医疗解决方案。该公司的产品包括Prizma,这是一种即插即用的医疗设备,具有电子病历功能和临床分级报告标准,可以测量生命体征;以及扩展Holter Patch系统,这是一种患者佩戴的多通道生物传感器,可以连续捕获长达14天的心电数据。该公司还开发了无线生命体征监测系统,这是一种提供对生命体征和生物特征的连续实时监测的解决方案。此外,它还提供监测服务,包括独立诊断检测设施监测和私人监测服务。该公司成立于2014年,总部设在以色列雷霍沃特。
接受Stryker Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Stryker和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧